Skip Navigation

Cardiovascular Research 2007 73(4):761-769; doi:10.1016/j.cardiores.2006.12.017
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Clements-Jewery, H.
Right arrow Articles by Curtis, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clements-Jewery, H.
Right arrow Articles by Curtis, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Neutrophil ablation with anti-serum does not protect against phase 2 ventricular arrhythmias in anaesthetised rats with myocardial infarction

Hugh Clements-Jeweryb, David J. Hearsea and Michael J. Curtisa,*

aCardiovascular Division, The Rayne Institute, St Thomas' Hospital, London, SE1 7EH, UK
bPresent address: Loyola University Medical Center, Maywood, IL, USA

* Corresponding author. Tel.: +44 207 1881095. Email address: michael.curtis{at}KCL.AC.UK

Objectives: Arrhythmias, including ventricular fibrillation (VF), occur in two phases after coronary obstruction, the first during the reversible stage of acute myocardial ischaemia (phase 1) and the second during evolution of the infarct (phase 2). We tested the hypothesis that phase 2 arrhythmias are mediated by actions of neutrophils accumulating within the infarct.

Methods: Male rats (n=10 per group) were randomized to receive 2 ml/kg i.p. of either rabbit anti-rat neutrophil anti-serum or normal rabbit serum. After 17 h, single stage left coronary artery ligation was performed under pentobarbitone anaesthesia, and ischaemia was maintained for 240 min.

Results: Anti-serum pretreatment caused almost total neutropenia, reducing neutrophils in circulating blood from 2096±274x103 to 8±8x103 per ml (p<0.05). It also blocked neutrophil accumulation in the infarct, reducing cardiac myeloperoxidase activity from 74.7±27.4 to 9±3 mU per mg protein (p<0.05). Despite this, there was no significant difference between control and anti-serum-treated rats in the incidence of phase 2 VF (30% in each group) tachycardia (VT; 60% vs 80%) or number of ventricular premature beats (VPBs).

Conclusion: Neutrophil accumulation within the evolving myocardial infarct does not mediate phase 2 VF.

KEYWORDS Antiarrhythmic agents; Neutrophil; Myocardial infarction; Ischaemia; Nitric oxide; Reperfusion; Ventricular arrhythmias

Abbreviations: IL-8, interleukin 8 • PAF, myeloperoxidase • MPO, platelet activating factor • SCD, sudden cardiac death • TNF{alpha}, tumor necrosis factor {alpha} • VF, ventricular fibrillation • VPB, ventricular premature beat • VT, ventricular tachycardia

Time for primary review 29 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.